New Products: Mayo's Cancer Dx; OGT's Cancer Panel; Natera's Panorama | GenomeWeb

The Mayo Clinic has launched CANCP, a 50-gene cancer panel that assesses hotspot mutations using next-generation sequencing with the goal of predicting a patient's response to therapy. The test is available to Mayo patients and providers worldwide through Mayo Medical Laboratories.


Oxford Gene Technology has launched SureSeq Solid Tumor Panel, a 60-gene cancer panel that uses hybridization-based enrichment and is assessed via next-generation sequencing. The panel was validated on formalin-fixed paraffin embedded tissue and covers the entire exons of the 60 genes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.